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Abstract
Background: Recognition of pathogens by immune receptors leads to activation of macrophages,
dendritic cells, and lymphocytes. Signals are communicated to enhance expression of target
molecules such as cytokines and adhesion molecules, depending on activation of various inducible
transcription factors, among which the family NF-κB transcription factors plays an evolutionarily
conserved and critical role. Classical activation of NF-κB involves phosphorylation,
polyubiquitination and subsequent degradation of the inhibitor molecules of NF-κB, referred to as
IκB. Modification of IκBα, one of the mammalian IκB isoforms, with the small ubiquitin-like modifier
(SUMO) results its protection from degradation.
Presentation of the hypothesis: SUMO-IκBα localizes in the nucleus. The nuclear SUMO-IκBα
pool may be dynamic. SUMO-IκBα functions as synergy control factor.
Testing the hypothesis: Immunoprecipitation from cellular fractions, 35S methionine pulse-
chase, and FRET assays should reveal the localization of SUMO-IκBα and the dynamics of the pool.
Expression of SUMOylation defective IκBα in an IκBα -/- background should yield insights into the
function of SUMO-IκBα.
Implication of the hypothesis: IκBα contains the required SUMOylation motif but IκBβ does
not. The suggested study would provide evidence whether or not IκBα and IκBβ can substitute
each other. In addition, the suggested assays would reveal a possible redundancy in controlling
transcriptional activity of NF-κB.
Background
For nearly two decades, the NF-κB activation pathway has
been the focus of experimental investigation. This path-
way is highly conserved among metazoans and plays key
roles in immune responses [1], cell proliferation [2],
inflammation [3], apoptosis [4], early embryonic devel-
opment [5], and many other processes.
Five members of mammalian NF-κB are described: NF-
κB1 (p50 and its precursor p105), NF-κB2 (p52 and its pre-
cursor p100), c-Rel, RelA (p65) and RelB [6–9], each of
which has a 300-residue Rel homology domain (RHD)
[1,10–14]. The C-terminal domains are responsible for
dimerization with other Rel proteins, but sequence-spe-
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cific interactions come primarily from loops in the N-ter-
minal domain [15].
Interaction of c-Rel, RelA and RelB with its inhibitors,
referred to as IκB, results in inactive complexes in the cyto-
plasm by masking the nuclear localization signal, which is
located at the C terminal end of the Rel homology domain
[1,10–14]. Currently, the inhibitor proteins IκBα, IκBβ,
IκBγ, IκBε, Bcl-3, and the Drosophila protein Cactus are
described and characterized [1,10–14].
In most cell types, NF-κB proteins are sequestered in the
cytoplasm in an inactive form through their non-covalent
association with the inhibitor IκB [7]. This association
masks the nuclear localization signal of NF-κB, thereby
preventing NF-κB nuclear translocation and DNA binding
activity [16]. NF-κB is activated through complex signal-
ing cascades that are integrated by activation of IκB kinase
complex (IKK) [17–21], which phosphorylates IκB bound
to NF-κB complexes as its substrates [22]. Consequently,
NF-κB proteins are translocated into the nucleus, where
they activate transcription of their target genes [11,12].
One of the key target genes regulated by NF-κB is its inhib-
itor IκBα. A feedback inhibition pathway for control of
IκBα gene transcription and down-regulation of transient
activation of NF-κB activity is described [23–25].
Signal-induced degradation of IκB family members has
traditionally been considered to regulate NF-κB activity.
However, accumulating evidence suggests that NF-κB
activity is also controlled by transcriptional repression
mediated by Rel-family members [26], phosphorylation
of RelA [27–29], NF-κB2 [30], and interaction of RelA and
NF-κB2 with histone deacetylases (HDACs) [31–33]. In
addition, modification of Dorsal by Smt3, the Drosophila
melanogaster  orthologs of NF-κB and SUMO-1, respec-
tively, has been demonstrated to regulate Dorsal-mediated
activation [34]. Indeed, modification of proteins at lysine
residues by ubiquitination, SUMOylation and acetylation
has been suggested as a means by which control of tran-
scriptional responses in general can be fine-tuned [35].
Small ubiquitin-like modifier (SUMO) is the best-charac-
terized member of a growing family of ubiquitin-related
proteins. SUMO is conjugated to target proteins using an
enzyme conjugation system similar to that of ubiquitin
[36,37]. The targets of SUMOylation suggest roles for pro-
tein SUMOylation in TNFR-mediated apoptosis [38] and,
paradoxically, protection from cell death [39]; nucleocy-
toplasmic transport [40–44] and subnuclear [45] localiza-
tion; and modulation of transcription factor activity
[46,47].
Among the perhaps more intriguing targets for SUMO
modification is IκBα. Polyubiquitination of IκBα chiefly
at lysine residues 21 and 22 targets it for proteasomal deg-
radation, whereas SUMOylation at lysine 21 appears to
protect IκBα from proteasome-mediated degradation
[48]. Furthermore, current data suggest that SUMOylation
of IκBα is an event that occurs in the nucleus, as pyruvate
kinase-IκBα fusion protein constructs that lack a func-
tional NLS fail to be modified by SUMO [49].
Presentation of the hypothesis
Desterro et al showed that a modified form of IκBα is
found in whole cell extracts from HEK 293, COS7, Jurkat,
and HeLa cell lines. Reciprocal immunoprecipitation
experiments with anti-IκBα and anti-SUMO-1 antibodies
demonstrated that IκBα is SUMOylated. Further experi-
mentation revealed that the level of SUMO-IκBα in whole
cell lysates from TNFα-stimulated COS7 cells remains
constant over time, whereas levels of unmodified IκBα
diminish and are replenished over time, consistent with a
previous study [23].
In parallel, cellular fractionation was carried out on these
cell lines. Cytoplasmic extracts showed little to no SUMO-
IκBα. Roff et al suggest that SUMO-IκBα is located in the
nucleus [50]. Supporting these data are data by Rodriguez
et al that suggest that IκBα retained in the nucleus after
LMB treatment is impervious to signal-induced degrada-
tion [52].
We therefore hypothesize that SUMO-IκBα localizes in
the nucleus, creating a nuclear pool of SUMO-IκBα,
which functions as synergy control factor.
Testing the hypothesis
Data from reporter gene assays suggest a role for SUMO-
IκBα in inhibiting NF-κB-dependent transcription [48].
What may however be complicating assessment of func-
tion is the fact that the reporter gene data derive from cells
in which SUMO is overexpressed. Given that little free
SUMO-1 is detectable in mammalian cells [53], and that
other members of the NF-κB pathway can crosstalk with
Ubc9, the SUMO E2 conjugating enzyme [54], overex-
pression of SUMO-1 may result in phenotypes that do not
correspond to in vivo situations. Moreover, all extant data
regarding SUMO-IκBα stem from transformed and/or
oncogenic cell lines, in which NF-κB activity cannot nec-
essarily be assumed normal. To date, no data show the
existence of SUMO-IκBα in primary cell lines. The follow-
ing experiments are proposed in order to assess the pres-
ence of SUMO-IκBα in primary cells, and the
physiological relevance of SUMO-IκBα.
Dynamics of the SUMO-IκBα pool
Hay et al stated that levels ranging from barely detectable
to almost 50% of the total IκBα can be found in the cell
types examined in their experiments [48,55]. The cell linesMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/39
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investigated were HEK 293, COS7, Jurkat and HeLa. In
order to establish the extent of IκBα SUMOylation in non-
transformed/non-oncogenic cell lines, the following
experiments might prove to be of considerable interest,
and should not entail significant technical difficulties.
From wild-type mice, isolate fibroblast and B- and T-cell
populations. These primary cells could be directly used in
the subsequent experiments. However, strategies for creat-
ing genetically stable, nontumorigenic immortalized cell
lines have been described [56,57]. The use of these or
comparable strategies for creating immortalized, geneti-
cally stable and nontumorigenic fibroblast, B- and T-cell
populations may therefore be useful for keeping these pri-
mary cells in culture for repeat experiments. With these
cell lines in hand, prepare cytoplasmic and nuclear frac-
tion of cells according to Roff et al [50], and whole cell
extracts as described by Desterro et al [48]. Reserve some
of the whole cell extracts for immunoprecipitation exper-
iments. Fractionate the cytoplasmic, nuclear and whole
cell extracts on a denaturing, reducing polyacrylamide gel
and transfer to membranes for immunoblot analysis with
an anti-IκBα antibody. In parallel, immunprecipitate with
anti-SUMO-1 antibody as described [58], followed by an
IκBα Western analysis, and vice versa [48].
Fluorescence resonance energy transfer (FRET) may
present an additional means by which a nuclear associa-
tion of SUMO-1 and IκBα could be demonstrated. CFP-
IκBα and SUMO-YFP have both been described [47,59],
as has the use of FRET microscopy to assess protein inter-
actions in living cell nuclei [60]. As stated previously,
overexpression experiments are potentially problematic
due both to interactions and localization that may occur
only when proteins are overexpressed. Therefore, the use
of a targeted knock-out/knock-in strategy to make CFP-
IκBα and SUMO-YFP double mutant mice might provide
the specificity needed in this experimental system. The
creation of such mice may be time consuming, yet the
techniques for making the mice are established.
Two different options suggest potential (and mutually
inclusive) roles for the pool in controlling NF-κB
responses and in nucleocytoplasmic transport. To address
the issue of static vs. dynamic pools of SUMO-IκBα, the
following experiment is suggested: A pulse-chase 35S-
methionine assay using cytoplasmic, nuclear and whole
extacts from cells at time points described above and by
Desterro et al [48,61].
Both nucleocytoplasmic trafficking and nuclear transla-
tion [62] would result in radiolabeled proteins being
found in the nucleus. However, most of these proteins are
not expected to associate with IκBα pulled down in the
immunoprecipitation. If, contrary to expectation, radiola-
beled proteins other than Rel family members are found
to associate with IκBα, the likelihood that any of these
would have the same molecular weight as SUMO-IκBα is
assumed to be manageably small. If no radiolabel is
detected at 36 kD, this suggests that the SUMO-IκBα pool
does not turn over appreciably. If radiolabel is detected at
36 kDa, this would suggest that, while the total pool of
SUMO-IκBα remains constant, this pool turns over.
Changing levels of radioactivity would suggest that
SUMO-IκBα turns over in the nucleus. This in turn may
indicate a key role in nucleocytoplasmic transport to
ensure a constant nuclear pool of IκBα.
SUMO-IκBα – a Synergy Control Factor
Cheng et al created IκBα/IκBβ knockout/knock-in mice,
and no abnormalities in viability or reproduction were
observed in these animals [63]. This suggests a functional
redundancy of these two IκB family members. However,
IκBα is rapidly degraded upon stimuli that trigger NF-κB
responses, whereas IκBβ is degraded at a significantly
slower rate [64]. In addition, the observation that deletion
of IκBα or IκBβ from the genome appears to be compen-
sated by other IκB family members [65,66], but that dele-
tion of IκBα results in neonatal lethality [67], together
hint at distinct roles for IκBα and IκBβ in NF-κB
responses. Inspection of the amino acid sequence of IκBβ
shows it lacks the Ψ KXE amino acid motif characteristic
of proteins that are SUMOylated. Therefore, IκBα/IκBβ
knockout/knock-in mice may phenocopy mice in which
wild-type IκBα is replaced with IκBαK21R, a mutant IκBα
for which SUMOylation, but not ubiquitination, is com-
promised.
The creation of IκBα/IκBβ knockout/knock-in mice indi-
cates that the creation of IκBαK21R  mice is feasible.
Whether or not such mutant mice phenocopy IκBα/IκBβ
knockout/knock-in mice, the viability of the IκBα/IκBβ
mouse suggests that IκBαK21R mutants would also live to
reproductive age. The following suggested experiments
should prove to be informative with respect to SUMO-
IκBα function: Create IκBα/IκBαK21R mutant mice using
established protocols [68,69]. Assess viability. Challenge
immune systems of mutant, wild-type and IκBα/IκBβ
knockout/knock-in mice as described [70,71], and assess
immune responses at the level of the organism. Establish
immortalized cell lines from the IκBα/IκBαK21R mutant
mice as described above. Stimulate an NF-κB response
using TNF-α in fibroblasts and lymphoid immortalized
cell lines from IκBαK21R mutant, wild type, and IκBα/IκBβ
knockout/knock-in mice and analyze the response.
The Ψ KXE amino acid sequence element required for
SUMOylation strongly resembles what is referred to as a
synergy control (SC) motif. SC motifs in certain transcrip-
tion factors (TFs) have been shown to confer onto TFs the
property of downregulating transcription at promotersMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/39
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with multiple binding sites for that TF, while promoters
with single TF binding sites are unaffected. When the SC
motifs are disrupted, transcription from promoters with
multiple sites is enhanced. SUMOylation of TFs at SC
motifs has been demonstrated in at least two cases
[34,72], suggesting role for SUMOylation in transcrip-
tional control.
Does SUMOylation of IκBα play a role in transcriptional
control? A nuclear pool of SUMO-IκBα may help titrate
NF-κB and influence transcriptional responses. As stated
previously, NF-κB transcriptional responses can be regu-
lated at the level of repression by certain Rel-family
homodimers [26], by phosphorylation [27–29], and by
interaction with histone deacetylases [31–33]. Therefore,
titration of NF-κB by nuclear IκBα, whether SUMOylated
or not, may be a redundant mechanism to control NF-κB
transcriptional activity. Given the general importance of
the NF-κB pathway, redundancy in controlling transcrip-
tional responses by ensuring a nuclear pool of IκBα may
be useful.
Implications of the hypothesis
IκBα contains the required SUMOylation but IκBβ does
not. The suggested study may demonstrate whether or not
IκBα and IκBβ can substitute each other. In addition, the
suggested assays would reveal a possible redundancy in
controlling transcriptional activity of NF-κB.
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